![Jork von Reden](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jork von Reden
Direttore/Membro del Consiglio presso PROTEO, INC.
Profilo
Jork von Reden currently works at Proteo, Inc., as Director from 2018, CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun, as Managing Director from 2016, and Wind Energy Trust Sp zoo, as Managing Director from 2009.
Mr. von Reden received his graduate degree from Technical University of Berlin.
Posizioni attive di Jork von Reden
Società | Posizione | Inizio |
---|---|---|
PROTEO, INC. | Direttore/Membro del Consiglio | 15/11/2018 |
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun
![]() CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun Miscellaneous Commercial ServicesCommercial Services CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun provides business consulting and investment services. The private company is based in Berlin, Germany. Jork von Reden has been the CEO of the German company since 2016. | Amministratore Delegato | 01/01/2016 |
Wind Energy Trust Sp zoo | Amministratore Delegato | 01/01/2009 |
Formazione di Jork von Reden
Technical University of Berlin | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Proteo, Inc.
![]() Proteo, Inc. Pharmaceuticals: MajorHealth Technology Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products. The firm focuses on the development of anti-inflammatory treatments for rare diseases. Its proprietary product Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands. The company's product is intended for the treatment of post-surgery damage to tissue, pulmonary hypertension, serious injuries caused by accidents, cardiac infarction, and other diseases, as well as for the complications resulting from organ transplantation. It has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded by Oliver Wiedow and Birge Bargmann on December 18, 1992 and is headquartered in Irvine, CA. | Health Technology |
CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun
![]() CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun Miscellaneous Commercial ServicesCommercial Services CFI Innovation GmbH Berlin Unternehmensberatung und Beteiligun provides business consulting and investment services. The private company is based in Berlin, Germany. Jork von Reden has been the CEO of the German company since 2016. | Commercial Services |
Wind Energy Trust Sp zoo |
- Borsa valori
- Insiders
- Jork von Reden